Lanifibranor is a pan-PPAR agonist evaluated in the Phase II NATIVE trial, which demonstrated significant results in achieving NASH resolution, reversing fibrosis, and improving both lipid profiles and insulin sensitivity in adult patients with non-cirrhotic MASH after just 24 weeks of treatment [193]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.